Cargando…

Durable complete response to immunotherapy with anti‐PD‐1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report

Although the optimal treatment method for metastatic oral cancer remains largely unknown, the present case suggests that immunotherapy is a potentially promising alternative for metastatic oral cancer in which other therapies are no longer effective.

Detalles Bibliográficos
Autores principales:	Sekido, Katsuhisa, Imaue, Shuichi, Tomihara, Kei, Tachinami, Hidetake, Yamagishi, Kentaro, Okazawa, Seisuke, Ikeda, Atsushi, Fujiwara, Kumiko, Noguchi, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405368/ https://www.ncbi.nlm.nih.gov/pubmed/34484745 http://dx.doi.org/10.1002/ccr3.4545

Ejemplares similares

Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Central mucoepidermoid carcinoma of the maxilla developing from a calcifying odontogenic cyst: A rare case report
por: Isshiki‐Murakami, Megumi, et al.
Publicado: (2021)

Treatment of severe micrognathia in an adult with distraction osteogenesis: A case report
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report
por: Kimura, Yutaro, et al.
Publicado: (2017)

Primary peri-implant oral intra-epithelial neoplasia/carcinoma in situ: a case report considering risk factors for carcinogenesis
por: Noguchi, Makoto, et al.
Publicado: (2017)

Successful multimodal treatment of intraoral salivary duct carcinoma in a patient with multiple lymph node metastases: a case report
por: Imaue, Shuichi, et al.
Publicado: (2017)

Mini‐microform cleft lip with complete cleft alveolus and palate: A case report
por: Fujiwara, Kumiko, et al.
Publicado: (2021)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
por: Guo, Liting, et al.
Publicado: (2017)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy
por: Nishii, Naoto, et al.
Publicado: (2018)

Durable Response to Nivolumab in a Patient With Hepatic Sarcomatoid Carcinoma: Evolutive Characterization of Genomic and Immunohistochemical PD-L1 Expression Findings
por: Queiroz, Marcello M., et al.
Publicado: (2022)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Nivolumab (PD-1 Inhibitor) Induced Exacerbation of Psoriasis
por: George, Anju, et al.
Publicado: (2020)

Bilateral Exudative Retinal Detachments Associated with Nivolumab Immunotherapy
por: Ajlan, Radwan S., et al.
Publicado: (2020)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer
por: Kataoka, Shunichi, et al.
Publicado: (2022)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy
por: Lattanzi, Michael, et al.
Publicado: (2018)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
por: Kijima, Yu, et al.
Publicado: (2021)

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
por: Farina, Benito, et al.
Publicado: (2023)

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
por: Boothe, James T., et al.
Publicado: (2017)

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy
por: Ilyinskii, Petr O., et al.
Publicado: (2018)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
por: Kang, Nai-Wen, et al.
Publicado: (2021)

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Hwang, Sohyun, et al.
Publicado: (2020)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2016)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

Combination immunotherapy of nivolumab plus ipilimumab in a lung cancer patient with Werner syndrome; a case report
por: Ikematsu, Yuki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vue7jd8lnlldjg1c9k5hdhij4s